Small Molecules Targeting PTPσ–Trk Interactions Promote Sympathetic Nerve Regeneration

• Published in: ACS chemical neuroscience Vol. 13; no. 5; pp. 688 - 699
• Main Authors: Blake, Matthew R., Gardner, Ryan T., Jin, Haihong, Staffenson, Melanie A., Rueb, Nicole J., Barrios, Amy M., Dudley, Gregory B., Cohen, Michael S., Habecker, Beth A.
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 02.03.2022
• Subjects: Chondroitin Sulfate Proteoglycans - metabolism; Humans; Nerve Regeneration - physiology; Phosphoric Monoester Hydrolases; Receptor-Like Protein Tyrosine Phosphatases, Class 2 - metabolism; Spinal Cord Injuries - metabolism; nerve regeneration; chondroitin sulfate proteoglycan; acrylamide; protein tyrosine phosphatase receptor sigma
• ISSN: 1948-7193; 1948-7193
• DOI: 10.1021/acschemneuro.1c00854

Chondroitin sulfate proteoglycans (CSPGs) prevent sympathetic nerve regeneration in the heart after myocardial infarction and prevent central nerve regrowth after traumatic brain injury and spinal cord injury. Currently, there are no small-molecule therapeutics to promote nerve regeneration through CSPG-containing scars. CSPGs bind to monomers of receptor protein tyrosine phosphatase sigma (PTPσ) on the surface of neurons, enhancing the ability of PTPσ to bind and dephosphorylate tropomyosin receptor kinases (Trks), inhibiting their activity and preventing axon outgrowth. Targeting PTPσ–Trk interactions is thus a potential therapeutic target. Here, we describe the development and synthesis of small molecules (HJ-01 and HJ-02) that disrupt PTPσ interactions with Trks, enhance Trk signaling, and promote sympathetic nerve regeneration over CSPGs.